慈濟醫療財團法人學術發展室之【116年度各類型研究計畫(如下圖)】即日起開始徵求，請留意部分計畫須於2/26(四)中午前提構想書，其他計畫收件截止日為115年5月15日(5)中午止，逾時不候。

※各院區之定義：北區(台北慈院)、中區(台中慈院、護理之家、三義慈院)、

                             南區(大林慈院、斗六慈院及嘉義診所)、東區(花蓮慈院、玉里慈院及關山慈院）。

 佛教慈濟醫療財團法人衍生新創事業管理辦法：

相關辦法請按此

 醫療專題管理辦法(AAM00A005)：

為統籌教學研究資源，提升院校的學術研究能量，俾使各項計畫能夠符合醫療志業任務導向、人才培育、基層發展與創新突破之各項醫療志業任務；是以制定『醫療專題管理辦法』將以臨床工作之研發、深化及強化為基調給予補助，以結合醫療志業之各項專才，並提升慈濟各院區之醫療水準，其辦法項下各計畫分為「特色醫療發展計畫」、「跨院區合作研究計畫」。

★初審：有意申請者須依各院區研究部(或負責單位)公告收件時間內繳交構想書，由研究部(或負責單位)彙整後，於115年2月26日(四)中午前繳交至法人學術發展室。

★複審：經通知通過之初審者，請依各院區研究部(或負責單位)公告收件時間內繳交計畫申請書及相關資料，由研究部(或負責單位)彙整後於每年5月15日前向法人學術發展室提出申請，法人學術發展室將會於每年12月31日前通知各計畫案之審核結果，如有任何問題請與本室承辦人員聯繫(Tel:03-8561825分機15815)，謝謝！

 研究成果競賽辦法(AAM00A004)：

為促進各院區間的學術研究風氣，鼓勵各院區同仁們從事學術研究，擬每年舉辦研究成果競賽，其重點說明如下：

1. 各項研究成果論文之研究應於慈濟醫療志業體內進行，且研究成果須以慈濟醫療志業名義發表於國內外醫學雜誌(須檢附論文抽印本或電子檔)，接受函不認列，且每一篇論文只能計算一次。

2. 參選之研究成果論文發表區間為每年1月1日至12月31日。

3. 參選文章性質限以第一或通訊作者名義之原著(Original article)期刊論文及綜論(Review article)，並依當年度最新JCR計算。

4. 得獎者依當年慈濟醫學年會公告報告方式進行報告，並於慈濟醫學年會時接受頒獎。

 其相關應用表單：

佛教慈濟醫療財團法人研究成果計分一覽表（E6A0022023-A5）

「淨斯本草飲相關論文」已發表連結：

序號	論文題目	下載
1	Artemisia Leaf Extract protects against neuron toxicity by TRPML1 activation and promoting autophagy/mitophagy clearance in both in vitro and in vivo models of MPP+/MPTP-induced Parkinson's disease.
2	Artemisia argyi extract ameliorates IL-17A-induced inflammatory response by regulation of NF-κB and Nrf2 expression in HIG-82 synoviocytes.
3	A combination of isoliquiritigenin with Artemisia argyi and Ohwia caudata water extracts attenuates oxidative stress, inflammation, and apoptosis by modulating Nrf2/Ho-1 signaling pathways in SD rats with doxorubicin-induced acute cardiotoxicity.
4	Artemisia argyi extract induces apoptosis in human gemcitabine-resistant lung cancer cells via the PI3K/MAPK signaling pathway.
5	Artemisia argyi exhibits anti-aging effects through decreasing the senescence in aging stem cells.
6	Artemisia argyi mitigates doxorubicin-induced cardiotoxicity by inhibiting mitochondrial dysfunction through the IGF-IIR/Drp1/GATA4 signaling pathway.
7	Kang Ru enhances paclitaxel's efficacy against breast cancer progression.
8	Clinical course of patients with severe SARS-CoV-2 infection co-treatment with Jin Si Herbal Tea in Eastern Taiwan: A retrospective cohort study.
9	Efficacy and Safety of Complementary Therapy With Jing Si Herbal Tea in Patients With Mild-To-Moderate COVID-19: A Prospective Cohort Study.
10	Protective effects of Scoparia dulcis L. extract on high glucose-induced injury in human retinal pigment epithelial cells.
11	Human adipose-derived stem cells preconditioned with a novel herbal formulation Jing Shi attenuate doxorubicin-induced cardiac damage.
12	Jing-Si Herbal Tea Suppresses H 2 O 2 -Instigated Inflammation and Apoptosis by Inhibiting Bax and Mitochondrial Cytochrome C Release in HIG-82 Synoviocytes.
13	Recuperative herbal formula Jing Si maintains vasculature permeability balance, regulates inflammation and assuages concomitants of "Long-Covid".
14	A prospective review of the health-promoting potential of Jing Si Herbal Tea.
15	Protective effects of Jing-Si-herbal-tea in inflammatory cytokines-induced cell injury on normal human lung fibroblast via multiomic platform analysis.
16	Novel anti-aging herbal formulation Jing Si displays pleiotropic effects against aging associated disorders.
17	Combined effect of traditional Chinese herbal-based formulations Jing Si herbal tea and Jing Si nasal drop inhibits adhesion and transmission of SARS- CoV2 in diabetic SKH-1 mice.
18	Ohwia caudata inhibits doxorubicin-induced cardiotoxicity by regulating mitochondrial dynamics via the IGF-IIR/p-Drp1/PARP signaling pathway.
19	Ohwia caudata aqueous extract attenuates doxorubicin-induced mitochondrial dysfunction in Wharton's jelly-derived mesenchymal stem cells.
20	Ohwia caudata extract relieves the IL-17A-induced inflammatory response of synoviocytes through modulation of SOCS3 and JAK2/STAT3 activation.
21	Ohwia caudata aqueous extract attenuates senescence in aging adipose-derived mesenchymal stem cells.
22	Efficacy of jing Si herbal tea in functional dyspepsia: A double-blind, randomized, placebo- controlled study.
23	Jing Si Herbal Tea Modulates Macrophage Polarization and Inflammatory Signaling in LPS-Induced Inflammation.
24	Chinese herbal prescriptions for COVID-19 management: Special reference to Taiwan Chingguan Yihau (NRICM101).
25	Therapeutic potential of Cordyceps militaris cultivated with Ginkgo biloba seeds for alleviating western diet-induced type 2 diabetes and diabetic nephropathy.
26	Protective effects of Cordyceps militaris against hepatocyte apoptosis and liver fibrosis induced by high palmitic acid diet.

 跨院區臨床科臨床服務與教學整合計劃辦法(第四版) :

  為推動與整合慈濟醫療在各院臨床服務、住院醫師及醫學生的教學、專科醫師訓練等方面，

  共同達成八院一家的理念，特此訂定【跨院區臨床科臨床服務語教學整合計畫辦法】之機制與程序，以利遵循。

  1.跨院區臨床科服務與教學整合計畫【申請書】

  2.跨院區臨床科服務與教學整合計畫【專案人員申請書】

   3.跨院區臨床科服務與教學整合計畫【專任人員補助放棄論文著作聲明書】